Table 2.
Incidence rates and cumulative incidence of outcomes during the at-risk period (n=39,782)
| Variablea | Affected Patients, n (%) | Incidence Rate per 1000 Patient-Years (95% CI) |
|---|---|---|
| Hospitalization for HF/volume overload | 8896 (22.4) | 243.9 (238.9 to 249.1) |
| Composite hospitalization for HF/volume overload or CV mortality | 10,805 (27.2) | 278.3 (272.9 to 283.7) |
| CV mortalityb | 2976 (7.5) | 55.8 (53.6 to 58.2) |
| All-cause mortality | 7646 (19.2) | 141.9 (138.3 to 145.6) |
| Myocardial infarction | 2396 (6.0) | 59.5 (57.1 to 61.9) |
| MACEc | 4994 (12.6) | 107.7 (104.6 to 111.0) |
| MACE+d | 12,221 (30.7) | 325.0 (319.2 to 331.0) |
| Hospitalization for atrial fibrillation | 2789 (7.0) | 69.7 (67.2 to 72.4) |
HF, heart failure; CV, cardiovascular; MACE, major adverse cardiovascular event; 95% CI, 95% confidence interval.
At-risk period began on dialysis day 181 and continued until death or censoring (as described in the text).
CV deaths defined as those attributed to myocardial infarction, atherosclerotic heart disease, cardiac arrhythmia, congestive HF, cardiomyopathy, cardiac arrest, valvular heart disease, pulmonary edema, cerebrovascular accident including intracranial hemorrhage, or ischemic brain damage/anoxic encephalopathy.
MACE is nonfatal myocardial infarction, nonfatal ischemic stroke, and CV death.
MACE+ is MACE plus arrhythmia, nonfatal hemorrhagic stroke, and HF.